Tumor Immunity in Neurologically Normal Patients
Observational Model: Case Control, Time Perspective: Prospective
Assessment of PND antibody titer, CTL activity, and clinical data in neurologically normal patients with SCLC and gynecologic tumors, with tumors unrelated to PNDs, and in normal control patients.
Duration of study
Robert Darnell, MD, PHD
United States: Institutional Review Board
|Rockefeller University Hospital||New York, New York 10021-6399|